par Declercq, Jozefien;Van Damme, Karel KFA;De Leeuw, Elisabeth;Maes, Bastiaan;Bosteels, Cedric;Tavernier, Simon J;De Buyser, Stefanie;Colman, Roos;Hites, Maya ;Verschelden, Gil ;Fivez, Tom;Moerman, Filip;Demedts, Ingel K;Dauby, Nicolas ;De Schryver, Nicolas;Govaerts, Elke;Vandecasteele, Stefaan Johan;Van Laethem, Johan;Anguille, Sébastien;van der Hilst, Jeroen;Misset, Benoit;Slabbynck, Hans;Wittebole, Xavier;Liénart, Fabienne ;Legrand, Catherine;Buyse, Marc;Stevens, Albert Dieter;Bauters, Fre;Seys, Leen LJM;Aegerter, Helena;Smole, Ursula;Bosteels, Victor;Hoste, Levi;Naesens, Leslie;Haerynck, Filomeen;Vandekerckhove, Linos;Depuydt, Pieter;van Braeckel, Eva;Rottey, Sylvie;Peene, Isabelle;Van Der Straeten, Catherine;Hulstaert, Frank;Lambrecht, Bart N
Référence The Lancet Respiratory Medicine, 9, 12, page (1427-1438)
Publication Publié, 2021
Référence The Lancet Respiratory Medicine, 9, 12, page (1427-1438)
Publication Publié, 2021
Article révisé par les pairs
Résumé : | Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome. |